Genetic Biomarkers of GLP-1 Response: Insights into Efficacy, Safety, and Patient Stratification from Real-World Clinico-Genomic Data
- In partnership with Illumina we leverage large-scale longitudinal clinico-genomic data, characterizing real-world heterogeneity in GLP-1 response, including variability in efficacy, safety, and tolerability across diverse patient populations
- In collaboration with PrecisionLife, we identify combinatorial genetic signatures that quantitatively predict efficacy (BMI and glycemic endpoints), enabling stratification of strong and weak responders in real-world settings
- We further explore genetic drivers of safety and tolerability, demonstrating how response-defined subgroups can support clinically actionable patient stratification, inform trial design and drug selection, and enable more precise deployment of GLP-1 and combination therapies